Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), scPharmaceuticals (SCPH – Research Report) and Invitae (NVTA – Research Report).
Fate Therapeutics (FATE)
In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Buy rating on Fate Therapeutics. The company’s shares closed last Thursday at $2.13, close to its 52-week low of $1.63.
According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Fate Therapeutics has an analyst consensus of Hold, with a price target consensus of $5.93, implying a 147.1% upside from current levels. In a report issued on November 8, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
scPharmaceuticals (SCPH)
In a report issued on November 8, Roanna Ruiz from Leerink Partners maintained a Buy rating on scPharmaceuticals, with a price target of $17.00. The company’s shares closed last Thursday at $4.70.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $19.20 average price target, a 295.1% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.
Invitae (NVTA)
In a report issued on November 8, Puneet Souda from Leerink Partners maintained a Hold rating on Invitae, with a price target of $1.00. The company’s shares closed last Thursday at $0.42.
According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Invitae has an analyst consensus of Moderate Sell, with a price target consensus of $1.33, an 117.5% upside from current levels. In a report issued on November 8, TD Cowen also maintained a Hold rating on the stock with a $0.75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FATE:
- Fate Therapeutics files $300M mixed securities shelf
- Fate Therapeutics reports Q3 EPS (46c) , consensus (57c)
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
- Is FATE a Buy, Before Earnings?
- Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
